Leland Gershell
Stock Analyst at Oppenheimer
(4.36)
# 409
Out of 4,734 analysts
123
Total ratings
41.96%
Success rate
28.28%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Initiates: Outperform | $76 | $54.54 | +39.35% | 1 | Dec 20, 2024 | |
| ARGX argenx SE | Reiterates: Outperform | $646 → $675 | $640.52 | +5.38% | 5 | Nov 21, 2024 | |
| ASND Ascendis Pharma | Maintains: Outperform | $190 → $180 | $128.13 | +40.48% | 10 | Nov 15, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $48 → $52 | $20.00 | +160.00% | 2 | Nov 11, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $135 → $147 | $111.89 | +31.38% | 2 | Nov 8, 2024 | |
| VERU Veru Inc. | Reiterates: Outperform | $5 | $0.98 | +412.61% | 8 | Nov 5, 2024 | |
| EPIX ESSA Pharma | Downgrades: Perform | n/a | $1.75 | - | 2 | Nov 4, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $65 → $73 | $46.88 | +55.72% | 8 | Oct 28, 2024 | |
| URGN UroGen Pharma | Reiterates: Outperform | $40 | $10.27 | +289.48% | 9 | Oct 16, 2024 | |
| IMVT Immunovant | Maintains: Outperform | $47 → $53 | $23.86 | +122.13% | 3 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $33.79 | - | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $43 | $13.70 | +213.87% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $7.14 | +320.17% | 2 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $3.53 | +239.94% | 2 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $150 → $25 | $1.14 | +2,092.98% | 9 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 → $28 | $18.13 | +54.44% | 5 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $25 | $4.55 | +449.45% | 3 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 → $73 | $37.35 | +95.45% | 7 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $20 | $3.09 | +547.25% | 5 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $29 | $22.78 | +27.30% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $35 | $6.75 | +418.52% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $1.31 | +663.36% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $3.20 | +56.25% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $3.76 | +139.36% | 2 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $23 → $20 | $1.45 | +1,279.31% | 3 | Nov 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $246.27 | - | 7 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $13 | $1.98 | +556.57% | 3 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $5 → $4 | $0.51 | +688.02% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $61.53 | - | 2 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $4.79 | - | 1 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7,200 | $0.22 | +3,286,070.70% | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Perform | n/a | $21.92 | - | 2 | Nov 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.62 | +1,808.40% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Perform | n/a | $0.56 | - | 5 | Mar 31, 2020 |
Rhythm Pharmaceuticals
Dec 20, 2024
Initiates: Outperform
Price Target: $76
Current: $54.54
Upside: +39.35%
argenx SE
Nov 21, 2024
Reiterates: Outperform
Price Target: $646 → $675
Current: $640.52
Upside: +5.38%
Ascendis Pharma
Nov 15, 2024
Maintains: Outperform
Price Target: $190 → $180
Current: $128.13
Upside: +40.48%
Dianthus Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $48 → $52
Current: $20.00
Upside: +160.00%
Ligand Pharmaceuticals
Nov 8, 2024
Maintains: Outperform
Price Target: $135 → $147
Current: $111.89
Upside: +31.38%
Veru Inc.
Nov 5, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.98
Upside: +412.61%
ESSA Pharma
Nov 4, 2024
Downgrades: Perform
Price Target: n/a
Current: $1.75
Upside: -
Soleno Therapeutics
Oct 28, 2024
Maintains: Outperform
Price Target: $65 → $73
Current: $46.88
Upside: +55.72%
UroGen Pharma
Oct 16, 2024
Reiterates: Outperform
Price Target: $40
Current: $10.27
Upside: +289.48%
Immunovant
Oct 9, 2024
Maintains: Outperform
Price Target: $47 → $53
Current: $23.86
Upside: +122.13%
Oct 3, 2024
Initiates: Perform
Price Target: n/a
Current: $33.79
Upside: -
Sep 25, 2024
Maintains: Outperform
Price Target: $15 → $43
Current: $13.70
Upside: +213.87%
Sep 24, 2024
Reiterates: Outperform
Price Target: $30
Current: $7.14
Upside: +320.17%
Sep 12, 2024
Reiterates: Outperform
Price Target: $12
Current: $3.53
Upside: +239.94%
Sep 3, 2024
Maintains: Outperform
Price Target: $150 → $25
Current: $1.14
Upside: +2,092.98%
Aug 12, 2024
Reiterates: Outperform
Price Target: $31 → $28
Current: $18.13
Upside: +54.44%
Aug 12, 2024
Maintains: Outperform
Price Target: $30 → $25
Current: $4.55
Upside: +449.45%
Aug 9, 2024
Reiterates: Outperform
Price Target: $74 → $73
Current: $37.35
Upside: +95.45%
Jul 10, 2024
Maintains: Outperform
Price Target: $14 → $20
Current: $3.09
Upside: +547.25%
Jun 6, 2024
Reiterates: Outperform
Price Target: $29
Current: $22.78
Upside: +27.30%
Apr 16, 2024
Upgrades: Outperform
Price Target: $35
Current: $6.75
Upside: +418.52%
Apr 9, 2024
Maintains: Outperform
Price Target: $10
Current: $1.31
Upside: +663.36%
Mar 28, 2024
Initiates: Outperform
Price Target: $5
Current: $3.20
Upside: +56.25%
Mar 21, 2024
Maintains: Outperform
Price Target: $9
Current: $3.76
Upside: +139.36%
Nov 15, 2023
Maintains: Outperform
Price Target: $23 → $20
Current: $1.45
Upside: +1,279.31%
Oct 11, 2023
Downgrades: Perform
Price Target: n/a
Current: $246.27
Upside: -
Apr 12, 2023
Maintains: Outperform
Price Target: $16 → $13
Current: $1.98
Upside: +556.57%
Mar 24, 2023
Maintains: Outperform
Price Target: $5 → $4
Current: $0.51
Upside: +688.02%
Feb 22, 2023
Downgrades: Perform
Price Target: n/a
Current: $61.53
Upside: -
Oct 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $4.79
Upside: -
Jun 4, 2021
Initiates: Outperform
Price Target: $7,200
Current: $0.22
Upside: +3,286,070.70%
Nov 25, 2020
Initiates: Perform
Price Target: n/a
Current: $21.92
Upside: -
Oct 23, 2020
Initiates: Outperform
Price Target: $50
Current: $2.62
Upside: +1,808.40%
Mar 31, 2020
Upgrades: Perform
Price Target: n/a
Current: $0.56
Upside: -